Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 201

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 201
---
techii/2025

Telephone access (listen-only):

Within the U.S. and Canada:
1 800-450-7155 (toll-free)

Outside of the U.S. and Canada:
+1 857-999-9155 (standard rates apply)

Conference ID:
9201360#</div>

Purpose of the Special Meeting

At the Special Meeting, FutureTech
is asking FutureTech stockholders to consider and vote upon:

Proposal No. 1 — The Business Combination Proposal —to consider and vote upon a proposal to approve (i) the Business Combination (as defined herein), (ii)
the adoption of the Agreement and Plan of Merger, dated as of September 16, 2024 (the “Merger Agreement”), by and among FutureTech,
Longevity Biomedical, Inc., a Delaware corporation (“Longevity”), LBI Merger Sub, Inc., a Delaware corporation and direct,
wholly-owned subsidiary of FutureTech (“Merger Sub”), and Bradford A. Zakes, solely in the capacity as seller representative,
and (iv) the transactions contemplated by the Merger Agreement, as more fully described elsewhere in the accompanying proxy statement/prospectus;

Proposal No. 2 — The Charter Approval Proposal — To consider and vote upon a proposal to adopt the Second Amended and Restated Certificate of Incorporation
in the form attached hereto as Annex B;

Proposal No. 3 — The Governance Proposals —To consider and vote upon, on a non-binding advisory basis, separately presented proposals with respect to certain
governance provisions in the Second Amended and Restated Certificate of Incorporation in accordance with SEC requirements;

Proposal No. 4 — The Director Election Proposal—To consider and vote upon a proposal to elect seven directors to our board of directors (our “Board”)
to serve as our directors for a term of three years expiring at the annual meeting of stockholders to be held in 2028 or until each such
director’s successor has been duly elected and qualified, or until each such director’s earlier death, resignation, retirement
or removal;

Proposal No. 5 — The Incentive Plan Proposal — to consider and vote upon a proposal to approve and assume the Longevity Biomedical, Inc. 2025 Equity Incentive
Plan (the “Equity Incentive Plan”) and any grants or awards issued thereunder; and

Proposal No. 6 — The Adjournment Proposal — to consider and vote upon a proposal to approve